«

»

Apr
17

The FDA has approved Merck’s Grastek tablet for grass pollen allergy, making it the second sublingual oral immunotherapy (SLIT)

The FDA has approved Merck’s Grastek tablet for grass pollen allergy, making it the second sublingual oral immunotherapy (SLIT) agent to gain that status following Greer’s Oralair. Grastek contains a single pollen extract of Timothy grass, which is cross-reactive with multiple other grass species. It is approved for adults up to age 65 and children as young as 5 years old.